Beijing Biotech
29
29
29
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 29 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (29)
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Role: lead
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
Role: lead
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Role: lead
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Role: lead
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Role: lead
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Role: lead
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
Role: lead
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
Role: lead
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
Role: lead
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Role: lead
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
Role: lead
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
Role: lead
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Role: lead
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Role: lead
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Role: lead
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Role: lead
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Role: lead
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Role: lead
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Role: lead
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Role: lead